UCB to Buy Candid Therapeutics for Up to .2 Billion

UCB to Buy Candid Therapeutics for Up to $2.2 Billion



UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company’s pipeline of experimental treatments for autoimmune and inflammatory diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *